Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone ‐sensitive prostate cancer

ConclusionsBaseline plasma miR‐141, miR‐200a, and miR‐375 levels are associated with baseline CTC count. Baseline miR‐375 was also associated with the trial endpoint of 28‐week PSA response. Our results provide evidence that circulating miRNA biomarkers may have value as prognostic biomarkers and warrant further study in larger prospective clinical trials.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fpros.23452

Source: The Prostate - November 6, 2017 Category: Urology & Nephrology Authors: Heather H. Cheng, Melissa Plets, Hongli Li, Celestia S. Higano, Catherine M. Tangen, Neeraj Agarwal, Nicholas J. Vogelzang, Maha Hussain, Ian M. Thompson, Muneesh Tewari, Evan Y. Yu Tags: ORIGINAL ARTICLE Source Type: research